MAPT and Alzheimer disease: Tau PET may thus have greater value for differential diagnosis of dementia as opposed to early disease where CSF biomarkers may have better sensitivity.54 Longitudinal studies are needed to address which biomarker (tau PET, Aβ PET, or CSF AD biomarkers) is best for estimation of progression to AD dementia in MCI.